Patient Management

Managing your metastatic non-small cell lung cancer patients on KEYTRUDA® (pembrolizumab)

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

In order to optimise treatment outcomes as well as patients’ quality of life, it is important to understand immune-related adverse events (irAEs), including their:

Early recognition and prompt appropriate treatment of irAEs:¹

Explore these related resources to learn more about managing your patients on KEYTRUDA

A guide to managing your metastatic non-small cell lung cancer patients on KEYTRUDA® (pembrolizumab) plus chemotherapy

Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]

KEYLearning Hub: digestible peer-to-peer videos on managing mNSCLC patients on KEYTRUDA® plus chemotherapy

Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]

KEYTRUDA® (pembrolizumab) monotherapy patient diary

Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]

KEYTRUDA® (pembrolizumab) in combination with chemotherapy patient diary

Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]

Find out more about KEYTRUDA® (pembrolizumab) in mNSCLC

Reference

1. Daniels GA et al. Emerg Med J. 2019;36:369–377.

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) 
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website.